| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1348 |
| Trial ID | NCT01087294 |
| Disease | B-Cell Leukemia | B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation |
| Year | 2010 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 100054|10-C-0054 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||||||
|
|||||||||||